Date: 2017-06-29
Type of information: Loan
Company: Melinta Therapeutics (USA - CT)
Investors: Oberland Capital (USA - NY)
Amount: $ 90 million
Funding type: loan
Planned used:
- Proceeds from this financing will be used primarily to fund commercialization activities for Baxdela®, which was recently approved by the FDA for the treatment of acute bacterial skin and skin structure infections).
Others:
- • On June 29, 2017, Melinta Therapeutics has entered into a loan and securities financing agreement with Oberland Capital. Under the terms of the agreement, Melinta is eligible to receive up to $90 million in the form of debt and equity. A significant portion was funded upon the approval of the NDAs for Baxdela™ (delafloxacin). The company may also draw down capital in three additional tranches at Melinta’s option and after the achievement of certain conditions.
Therapeutic area: Infectious diseases
Is general: Yes
